Quickly verify claims by accessing the underlying experimental data and figures.
Press Enter ↵ to solve
Fuel Your Discoveries
"Science is not about why, it's about why not."
- Portal 2
Quick Answer
Copied
Core claim (what the authors built)
The paper presents NDAM, an AFM-based single-molecule diagnostic workflow that uses nickase editing to create a site-specific single-strand break, then DNA nanotags (DNA tetrahedra/origamis) to label the edited locus, and finally a YOLOv5l model to automatically detect/classify objects in AFM images; they report rapid AFM-image classification (370 origamis in 1.21 s) and clinical mutation detection for KRAS G12R (PDAC/CRC) and TP53 R175H (CRC) with accuracy claimed to be comparable to Sanger/qPCR.
Long Answer
Paper-at-a-glance (visual first)
AFM SMDNickase editingDNA origami tagsYOLOv5lFFPE clinical test
NDAM concept flow: nick a target DNA locus → insert extension DNA with mutation-discriminating sticky ends → hybridize shape-resolved DNA nanotags → image by AFM → detect/classify AFM objects via YOLOv5l → infer mutation status.
Figure 1 — Reported NE cleavage efficiencies (urea-PAGE derived)
The paper reports cleavage efficiencies for multiple target sites using urea-PAGE analysis via ImageJ, with example efficiencies of ~97.9%, 91.1%, 76.5%, 82.3%, and 68.9% for distinct NE-treated constructs.
Figure 2 — Claimed YOLOv5l throughput + accuracy
The abstract states that the YOLOv5l algorithm can classify 370 structures in 1.21 seconds with 98% accuracy.
The paper states: KRAS G12R detection in FFPE samples with 6 PDAC positives out of 37 and 0 CRC positives (CRC sample count stated as 29 in the abstract and as 27 elsewhere in the ethics/source description—see limitations/conflicts below). For TP53 R175H in CRC, it states 2 positives out of 22.
Mechanistic evaluation (what is known vs inferred)
The paper presents nickases (nickase versions of Cas9 and sequence-specific nicking endonucleases) as the locus-specific step that creates nicks/single-strand breaks, enabling insertion/extension of exogenous DNA with distinct sticky ends that hybridize to shape-resolved nanotags.
2) AFM readout is “shape → object identity”
The measurement output is AFM topography, then ML recognizes and classifies objects in images. The paper’s stated automation goal is to remove manual contour/object selection bottlenecks.
The causal chain for clinical mutation calling is: (i) PCR amplification from FFPE DNA, (ii) nickase editing designed to differ between wild-type vs mutant alleles, (iii) nanotag labeling, (iv) ML object detection, and (v) mutation status inference. The paper reports comparisons/verification against Sanger sequencing and qPCR.
Critical appraisal (skeptical, evidence-weighted)
Major strengths
End-to-end pipeline concept: combines site-specific enzymatic editing, modular DNA nanostructure tagging, high-resolution AFM, and automated ML detection in one workflow.
Automation focus is explicit: throughput/latency claims (1.21 s for 370 structures) target the manual bottleneck.
Clinical proof-of-concept uses FFPE cohorts: they attempt real patient material for KRAS G12R (PDAC/CRC) and TP53 R175H (CRC).
Major limitations / blind spots
Cohort-count inconsistency: the text/metadata shows different CRC counts (ethics says 27 CRC, abstract says 29 CRC) which complicates how one reads mutation prevalence and diagnostic statistics. This should be reconciled to avoid silent reporting errors.
Generalization uncertainty: the clinical part targets only two hotspot mutations (KRAS G12R and TP53 R175H). It is unknown (from the provided text alone) how robust the approach is across other loci, allele contexts, or different FFPE fragmentation profiles.
False-positive pathways aren’t fully bounded in the text excerpt: for gene-editing based readouts, off-target nicking, incomplete cleavage, or nonspecific DNA hybridization could lead to spurious tags; the paper claims low false positives, but the excerpt provided does not include complete negative-control and error-rate accounting needed to fully assess specificity.
ML evaluation details may be incomplete without full supplementary figures: YOLO performance is reported (98% accuracy; 370 objects in 1.21 s), but robust assessment requires clarity on train/test splits, external validation datasets, domain shift (different AFM instruments/operators/batch conditions), and calibration. Those details are not fully extractable from the excerpt alone.
Directed “what would disprove it?” checklist (falsifiability)
Based strictly on the workflow described, the highest-impact disconfirmations would be:
Demonstrate that YOLOv5l misclassifies AFM-object shapes under new AFM conditions (instrument/operator/batch) producing false mutation calls.
Show that nickase + tagging yields signals at loci lacking the target mutation (e.g., via allele-matched negative controls), indicating nonspecific hybridization or off-target nicking.
In a larger independent cohort, show discordance vs Sanger/qPCR (especially for low-frequency alleles and across varied FFPE quality).
Author-declared conflicts (skeptical check)
The paper excerpt includes a statement that the authors declare no competing interests.
Explore deeper on BGPT
Run a Science AI agent (iterative, tool/code-based critique)
This will attempt to extract any additional figure/table values available from the full text/SI and then stress-test the reported performance claims against standard evaluation pitfalls (data leakage, domain shift, and mismatch between ML object metrics and clinical endpoints).
Author reviews on BGPT
Feedback:
Updated: April 28, 2026
BGPT Paper Review
Study Novelty
90%
The novelty lies in the specific integration of nickase-based locus editing with shape-resolved DNA origami/tetrahedron nanotags for AFM readout, plus YOLOv5l automation for single-molecule AFM image classification, applied to clinical FFPE mutation calling for two hotspot mutations.
Scientific Quality
70%
Overall scientific quality appears strong for a proof-of-concept engineering/automation study (end-to-end pipeline; explicit performance numbers; clinical verification claimed). Main red flags are limited extractable evaluation detail from the provided text (e.g., training/test splits, external domain validation, full confusion-matrix-to-clinical mapping) and an inconsistency in CRC sample counts across sections that should be reconciled.
Study Generality
70%
It is relatively general as a platform pattern (nickase editing + DNA nanostructure tagging + AFM + ML), but the clinical demonstration is limited to two hotspots and a small cohort size typical of early proof-of-concept. Generalization to broader panels and different laboratories remains unproven.
Study Usefulness
70%
Usefulness is high for the niche of AFM-based single-molecule genotyping and for demonstrating ML automation in such pipelines; however, translation to routine diagnostics will require clearer calibration of specificity/false positives, cohort-scale validation, and infrastructure/automation for AFM.
Study Reproducibility
60%
Methods are described with materials and procedural steps, and the paper states code availability for YOLOv5l and training/detection utilities via Zenodo. Reproducibility is still limited by missing excerpt-level details (exact train/test splits, full parameterization, AFM acquisition settings, and comprehensive performance reporting across independent datasets) and by potential AFM domain sensitivity.
Explanatory Depth
70%
Mechanistic explanation of the editing→tagging→AFM→ML mapping is reasonably clear and backed by in vitro localization experiments. But the excerpt does not show deep mechanistic quantification of systematic error sources (e.g., off-target nicking rates, hybridization specificity under FFPE-derived fragmentation) that would raise explanatory depth for clinical performance.
It will parse the paper’s reported mutation/efficiency numbers into structured tables, compute mutation-positive rates, and generate comparison charts mapping ML object-detection metrics to clinical verification endpoints.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The idea that NDAM’s diagnostic accuracy is mainly limited by ML model capacity (rather than biochemical editing/tagging specificity) is less convincing given the pipeline’s explicit dependence on nickase activity and the authors’ own stated future need to minimize off-target effects.
Assuming that high in vitro object classification accuracy guarantees robustness in FFPE samples is unlikely; the paper itself emphasizes remaining work such as mutant-to-wild-type ratio quantification and improved editing precision, implying practical translation challenges beyond ML object recognition.
Quick Answer
Long Answer
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
